Cord-derived stem cell therapy tied to no deaths in tiny newborn trial

Axiom reports zero mortality over two years in nine newborns treated for two often-fatal brain conditions — an early but striking signal.

Axiom Biosciences has reported that a phase 1 trial of its stem cell therapy for newborn neurological disease saw no deaths over two years. The trial dosed nine newborns: five with severe intraventricular hemorrhage and four with hypoxic-ischemic encephalopathy. By Axiom's account, the first-year mortality for these conditions is normally around 46 percent. The company also reported no treatment-related serious adverse events, no need for anti-epileptic medication, and no observed cerebral palsy, a condition it says affects about half of such patients.

The therapy uses mesenchymal stem cells derived from Wharton jelly, an MSC-rich material in the umbilical cord, co-developed with South Korea's Medinno. The cells are conditioned rather than engineered or gene-edited, and are delivered directly into the brain's ventricles to bypass the blood-brain barrier. The FDA has granted rare pediatric disease designations for both indications.

If the effect holds, this touches a need with almost no current answer: survival for newborns facing conditions that kill nearly half of them in the first year. A conditioned, cord-derived cell product avoids the cost and complexity of engineered therapies, which could matter for eventual access. It also builds on a broader MSC field — Mesoblast's Ryoncil won FDA approval in 2024 after two rejections.

The caveats are large. This is a nine-patient phase 1 study, the efficacy is preliminary, and the mortality and outcome figures come from Axiom's own press release. Watch for the planned phase 2b trials and an expansion into adult ischemic stroke to test whether the signal survives larger, controlled study.

Source: Fierce Biotech